濮阳东方在哪濮阳市东方医院咨询热线,濮阳东方医院割包皮口碑很好价格低,濮阳东方医院看男科技术非常专业,濮阳东方医院公交站,濮阳东方看妇科病非常的专业,濮阳东方男科医院看病好不好,濮阳东方医院妇科在哪

The US Department of Education has opened an investigation into the Ohio State University's handling of former students' allegations of sexual misconduct by a school doctor, according to the university.The federal investigation will be conducted by the department's Office for Civil Rights (OCR), which oversees Title IX complaints, the school said in a statement Thursday.The inquiry, led by the OCR's regional office in Cleveland, Ohio, "will examine whether the university is responding promptly and equitably to complaints and reports by former students," the statement said, "including allegations that employees knew or should have known about the sexual misconduct and allowed the abuse to continue."The scandal surrounding the alleged actions of the late Dr. Richard Strauss has grown since the university first announced in April its own investigation, headed by the law firm Perkins Coie, to look into claims made by male former athletes on 14 sports teams.Since then, more than 100 former Ohio State University students have reported firsthand accounts of sexual misconduct by Strauss, the school said last month.Some of them, mostly former student athletes, have come forward to publicly claim that Strauss sexually abused them under the guise of a medical examination.According to the school, the alleged abuse took place between 1979 and 1997."We welcome the involvement and careful oversight of OCR and look forward to providing any information we can," said Gates Garrity-Rokous, the school's vice president and chief compliance officer, in a statement about the US Department of Education's investigation."We responded promptly and appropriately to the allegations received in April about Dr. Strauss," Garrity-Rokous continued. "We are confident in the independence and thoroughness of the investigation we launched then as well as our ongoing commitment to transparency."The-CNN-Wire 1910

The road to college sometimes has twists and turns, for Rehan Staton, the road to Harvard Law included recovering from injuries, growing up with a single parent, and years as a sanitation worker.Staton’s life changed when he was 8, when his mother left, according to CNN. His father raised him and his brother, reportedly working multiple jobs to make ends meet. Staton struggled in high school, and graduated with the help of a tutor his dad found. An injury before graduating meant an athletic scholarship was out of reach.When his dad suffered a stroke, Staton and his brother took jobs as sanitation workers to support the family. While collecting garbage, Staton found time to attend the University of Maryland.He spent his college years waking up early and collecting garbage before class. Staton says it was because of encouragement from his sanitation coworkers that he kept going to class. He graduated with a history degree and a GPA of 3.84 in December 2018. Staton was profiled in the University of Maryland’s campus paper.Staton wasn’t done. After graduating he took a job to support his dad and didn’t give up on higher education. He applied to 9 schools. His cousin reportedly had the idea to record Staton opening letters from schools he applied to, to capture his reactions. Staton says the admissions process was “super random at times” and encourages people not to “internalize it.”He is now headed to Harvard Law School this fall, and his excitement after years of hard work was caught on camera. His reaction to Harvard is about 6 minutes into the video.There is currently a gofundme account set up to help Staton raise the money needed to attend Harvard. He will reportedly be taking classes online this fall and hopes to be on campus soon. 1771

The Senate Intelligence Committee voted 10-5 closed doors Wednesday to advance Gina Haspel's nomination as President Donald Trump's CIA director pick, advancing the nominee to a full floor vote where she looks all but assured to win Senate confirmation.Two of the committee's seven Democrats have said they are supporting Haspel, including Virginia's Sen. Mark Warner, the top Democrat on the panel. Haspel currently has more than enough support to win confirmation, as Warner was one of three Democrats to announce Tuesday that they were voting for her, bringing the total to five.   602

The Scripps National Spelling Bee is welcoming applicants for its second year of RSVBee, the invitational program that creates more opportunities for champion spellers to compete in the national finals in National Harbor, Maryland.Last year, more than 230 students competed in the national finals through RSVBee, including the 2018 Champion, Karthik Nemmani, from McKinney, Texas.To be eligible, students must attend a school that is enrolled in the Scripps National Spelling Bee program and be a school or community spelling champion during the 2018-19 school year. Students who previously competed in the national finals also are eligible to apply. Parents can complete the online application form on behalf of their children between now and March 22, 2019.There are new application and invitation acceptance guidelines for RSVBee: 841

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274